Remington's Pharmaceutical Sciences
| [0037]
|
Resting and rate-dependent depression of Vmax of guinea-pig ventricular action potentials by amiodarone and desethylamiodarone
| [0084]
|
Frequency-dependent effect of amiodarone on atrioventricular nodal function and slow-channel action potentials: evidence for calcium channel-blocking activity
| [0084]
|
BGP-15, a nicotinic amidoxime derivate protecting heart from ischemia reperfusion injury through modulation of poly(ADP-ribose) polymerase
| [0084]
|
Should amiodarone or lidocaine be given to patients who arrest after cardiac surgery and fail to cardiovert from ventricular fibrillation?
| [0084]
|
Intravenous amiodarone in intensive care. Time for a reappraisal?
| [0084]
|
Binding of amiodarone by serum proteins and the effects of drugs, hormones and other interacting ligands
| [0084]
|
Cardiac □-adrenoreceptor modulation by amiodarone
| [0084]
|
Pulmonary fibrosis induced in the hamster by amiodarone and desethylamiodarone
| [0084]
|
Amiodarone pretreatment effects on ischemic isovolumic rat hearts: a P-31 nuclear magnetic resonance study of intracellular pH and high-energy phosphates contents evolutions
| [0084]
|
Rapid pulmonary phospholipid accumulation induced by intravenous amiodarone Can
| [0084]
|
Amiodarone pharmacokinetics
| [0084]
|
Disposition of amiodarone and its proximate metabolite, desethylamiodarone, in the dog for oral administration of single-dose and short-term drug regimens
| [0084]
|
Cellular accumulation of amiodarone and desethylamiodarone in cultured human cells. Consequences of drug accumulation on cellular lipid metabolism and plasma membrane properties of chronically exposed cells
| [0084]
|
The effect of amiodarone, a new anti-anginal drug, on cardiac muscle
| [0084]
|
Role of phospholipase A inhibition in amiodarone pulmonary toxicity in rats
| [0084]
|
Serum concentrations of amiodarone during long term therapy. Relation to dose, efficacy and toxicity
| [0084]
|
Amiodarone pharmacokinetics
| [0084]
|
Mechanisms of amiodarone and desethylamiodarone cytotoxicity in nontransformed human peripheral lung epithelial cells
| [0084]
|
Cytotoxic interaction between amiodarone and desethylamiodarone in human peripheral lung epithelial cells
| [0084]
|
Effects of vitamin E on amiodarone-induced cytotoxicity in isoalted hamster lung cells
| [0084]
|
Tissue drug accumulation and ultrastructural changes during amiodarone administration in rats
| [0084]
|
Metastasis: recent discoveries and novel treatment strategies
| [0084]
|
Distinct mechanisms of tumor invasion and metastasis
| [0084]
|
The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited
| [0084]
|
Therapy for metastatic melanoma: the past, present, and future
| [0084]
|
PI3K/Akt signalling pathway and cancer
| [0084]
|
Protective effect of amiodarone but not N-desethylamiodarone on postichemic hearts by the inhibition of mitochondrial permeability transition
| [0084]
|
Concentration dependent mitochondrial effect of amiodarone
| [0084]
|
A novel SOD-mimetic permeability transition inhibitor agent protects ischemic heart by inhibiting both apoptotic and necrotic cell death
| [0084]
|
Synthesis and evaluation of the permeability transition inhibitory characteristics of paramagnetic and diamagnetic amiodarone derivates
| [0084]
|
Metastatic inefficiency
| [0084]
|
Molecular networks that regulate cancer metastasis
| [0084]
|
Metastasis: a question of life or death
| [0084]
|
Cancer sternness and metastasis: therapeutic consequences and perspectives
| [0084]
|
The pro-survival function of Akt kinase can be overridden or altered to contribute to induction of apoptosis
| [0084]
|
Significance of talin in cancer progression and metastasis
| [0084]
|
The phosphatidylinositol 3-Kinase AKT pathway in human cancer
| [0084]
|
The Phosphoinositide 3-Kinase Pathway in Human Cancer: Genetic Alterations and Therapeutic Implications
| [0084]
|
Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity
| [0084]
|